BioLine Rx Ltd. has announces the following changes in its senior management. Ella Sorani, Ph.D., has been appointed as the registrant's Vice President Development. Dr. Sorani joins the registrant with 16 years of experience in drug development in the global R&D division at Teva Pharmaceuticals Industries Ltd. (Teva), where she served in a number of management positions. In her most recent position as Senior Director and Global Project Leader, Dr. Sorani led the global development of one of Teva's leading innovative late stage compounds. Abi Vainstein-Haras, M.D., has been appointed as the registrant's Vice President Clinical and Medical Affairs. From June 2014 to January 2017, Dr. Vainstein-Haras served as the registrant's Senior Medical Director responsible for the clinical development of all the registrant's clinical phase projects. Prior to joining the registrant, from 2012 to 2014, she served as the Director and Clinical Program Leader for COPAXONE at Teva, and from 2007 to 2012, she served in a number of medical positions in Innovative R&D at Teva. In the framework of the foregoing appointments, Merril Gersten, Ph.D., will be leaving her position as the registrant's Chief Scientific Officer as of March 31, 2017.